ClinicalTrials.gg
CompletedNCT00835406Updated Jul 9, 2009Results posted

Alendronate Sodium 70 mg Tablet Versus Fosamax® Under Fasting Conditions.

A Phase 1 interventional study of Alendronate Sodium Tablets 70mg and Fosamax® Tablets 70mg in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in Canada. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-07-09.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The objective of this study is to compare the rate and extent of absorption of alendronate sodium 70 mg tablets (test) versus Fosamax® 70 mg tablets (reference) administered as a single dose of 70 mg under fasting conditions. A review of pharmacokinetic data demonstrates Alendronate Sodium Tablets, 70 mg, manufactured and distributed by TEVA Pharmaceuticals USA are bioequivalent to Fosamax® Tablets, 70 mg, manufactured by Merck Sharp \& Dohme, USA.

Read the detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Healthy Subjects
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects will be males, non-smokers, between 18 and 45 years of age.
  • Subjects' weight will be within 15% of their ideal body weight based on the Table of "Desirable Weight of Adults", Metropolitan Life Insurance Company, 1983
  • Subjects should read, sign, and date an Form prior to any study procedures.
  • Subjects must complete all screening procedures within 28 days prior to the administration of study medication.

Exclusion criteria

Exclusion Criteria:

  • abnormalities found during medical screening.
  • Any history or presence of significant neurological, hepatic, renal, endocrine, cardiovascular, pulmonary, hematologic, immunologic, psychiatric or metabolic disease.
  • Any clinically significant history of ongoing gastrointestinal problems or problems known to interfere with the absorption, distribution, metabolism or excretion of drugs (e.g. chronic diarrhea, inflammatory bowel diseases).
  • Clinically significant illnesses within 4 weeks of the administration of study medication.
  • Abnormal laboratory tests judged clinically significant.
  • or vital signs abnormalities (clinically significant).
  • History of allergic reactions to alendronate or other related drugs (e.g. clodronate, etidronate and pamidronate).
  • History of allergic reactions to heparin.
  • Any food allergies, intolerances, restrictions, or special diet which in the opinion of the medical subinvestigator, contraindicates the subject's participation in this study.
  • Positive urine drug screen at screening or at check-in of period I.
  • Positive testing for , or at screening.
  • Use of an drug or participation in an investigational study, within 30 days prior to administration of the study medication.
  • Recent donation of plasma (500 mL) within 7 days or recent donation or significant loss of whole blood (450 mL) within 56 days prior to administration of the study medication.
  • History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than two units of alcohol per day (1 Unit = 150mL of wine or 360 mL of beer or 45 mL of alcohol 40%).
  • Recent history of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana, pot) within 3 months of the screening visit or hard drugs (such as cocaine, phencyclidine (PCP), crack) within 1 year of the screening visit.
  • Subjects who have used tobacco within 90 days of the start of the study.
  • Subjects who have taken prescription medication 14 days preceding administration of study medication or over-the-counter products 7 days preceding administration of study medication, except for topical products without systemic absorption.
  • Subjects who have taken any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication (examples of inducers: barbiturates, carbamazepine, phenytoin, , rifampin/rifabutin; examples of inhibitors: antidepressants, cimetidine, diltiazem, erythromycin, ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine).
  • Subjects who have undergone clinically significant surgery 4 weeks prior to the administration of the study medication.
  • Any reason which, in the opinion of the medical subinvestigator, would prevent the subject from participating in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Alendronate Sodium First

    70 mg Alendronate Sodium Tablets test product dosed in first period followed by 70 mg Fosamax® Tablets reference product dosed in second period

    Drug: Alendronate Sodium Tablets 70mg

  • Active comparator
    Fosamax® First

    70 mg Fosamax® Tablets reference product dosed in first period followed by 70 mg Alendronate Sodium Tablets test product dosed in second period.

    Drug: Fosamax® Tablets 70mg

Interventions

06

What researchers measure

Primary outcomes

  1. Bioequivalence Based on Rmax

    Rmax = maximum rate of urinary excretion

    Time frame: Urine collected over 36 hour period

  2. Bioequivalence Based on Ae0-36

    Ae0-36 = cumulative urine excretion

    Time frame: Urine collected over 36 hour period

07

Results

Posted Jun 11, 2009

Participant flow

Period: First Intervention
Participant flow — Period: First Intervention
MilestoneAlendronate Sodium FirstFosamax® First
Started7070
Completed6869
Not completed21
Withdrew: Adverse event01
Withdrew: Withdrawal by subject20
Period: Washout of 7 Days
Participant flow — Period: Washout of 7 Days
MilestoneAlendronate Sodium FirstFosamax® First
Started6869
Completed6867
Not completed02
Withdrew: Withdrawal by subject02
Period: Second Intervention
Participant flow — Period: Second Intervention
MilestoneAlendronate Sodium FirstFosamax® First
Started6867
Completed6867
Not completed00

Outcome measures

PrimaryBioequivalence Based on Rmax

Rmax = maximum rate of urinary excretion

Time frame:
Urine collected over 36 hour period
Reported as:
Geometric mean · ng/mL
Bioequivalence Based on Rmax
ng/mLAlendronate SodiumFosamax®
Bioequivalence Based on Rmax73.96 ± 40.4873.99 ± 39.00
Statistical analysis
  • Alendronate Sodium vs Fosamax® · Ratio of the mean: 97.94 · 90% CI 90.96 to 105.45Bioequivalence is established when 90% Confidence Interval falls within 80 - 125
PrimaryBioequivalence Based on Ae0-36

Ae0-36 = cumulative urine excretion

Time frame:
Urine collected over 36 hour period
Reported as:
Geometric mean · ng/mL
Bioequivalence Based on Ae0-36
ng/mLAlendronate SodiumFosamax®
Bioequivalence Based on Ae0-36219.28 ± 127.25213.44 ± 118.05
Statistical analysis
  • Alendronate Sodium vs Fosamax® · Ratio of the mean: 100.36 · 90% CI 92.85 to 108.48Bioequivalence is established when 90% Confidence Interval falls within 80 - 125

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Alendronate Sodium FirstFosamax® FirstTotal
<=18 years000
Between 18 and 65 years7070140
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Alendronate Sodium FirstFosamax® FirstTotal
Female000
Male7070140
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Alendronate Sodium FirstFosamax® FirstTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White7069139
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Alendronate Sodium FirstFosamax® FirstTotal
Canada7070140
08

Study locations

1 site
  • Anapharm Inc.
    Sainte-Foy, Quebec GIV2K8, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2000, a primary completion of Jul 2000 and a completion of Jul 2000. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 8 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2009
First posted
Feb 3, 2009
Start
Jun 2000
Primary completionActual
Jul 2000
CompletionActual
Jul 2000
Results first posted
Jun 11, 2009
Last update
Jul 9, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00835406
First posted
Feb 3, 2009
Start date
Jun 2000
Primary completion
Jul 2000
Completion
Jul 2000
Results posted
Jun 11, 2009
Last update
Jul 9, 2009

Study contacts

Eric Masson, Pharm.D.
principal investigator · Anapharm

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alendronate

Start the discussion